Novel pathways in the treatment of major depression

Focus on the glutamatergic system

Carmine Tomasetti, Chiara Montemitro, Annastasia L.C. Fiengo, Cristina Santone, Laura Orsolini, Alessandro Valchera, Alessandro Carano, Maurizio Pompili, Gianluca Serafini, Giampaolo Perna, Federica Vellante, Giovanni Martinotti, Massimo D. Giannantonio, Yong Ku Kim, Marco D. Nicola, Antonello Bellomo, Antonio Ventriglio, Michele Fornaro, Domenico D. Berardis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further “neurobiological targeted” approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.

Original languageEnglish
Pages (from-to)381-387
Number of pages7
JournalCurrent Pharmaceutical Design
Volume25
Issue number4
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Depression
Depressive Disorder
Glutamic Acid
Therapeutics
Ketamine
Synaptic Transmission
Psychiatry
Comorbidity
Drug Therapy
Research

Keywords

  • Antidepressants
  • Antipsychotics
  • Depressive disorders
  • Glutamate
  • Ketamine
  • Mglur
  • Nmda
  • Postsynaptic density

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., ... Berardis, D. D. (2019). Novel pathways in the treatment of major depression: Focus on the glutamatergic system. Current Pharmaceutical Design, 25(4), 381-387. https://doi.org/10.2174/1381612825666190312102444

Novel pathways in the treatment of major depression : Focus on the glutamatergic system. / Tomasetti, Carmine; Montemitro, Chiara; Fiengo, Annastasia L.C.; Santone, Cristina; Orsolini, Laura; Valchera, Alessandro; Carano, Alessandro; Pompili, Maurizio; Serafini, Gianluca; Perna, Giampaolo; Vellante, Federica; Martinotti, Giovanni; Giannantonio, Massimo D.; Kim, Yong Ku; Nicola, Marco D.; Bellomo, Antonello; Ventriglio, Antonio; Fornaro, Michele; Berardis, Domenico D.

In: Current Pharmaceutical Design, Vol. 25, No. 4, 01.01.2019, p. 381-387.

Research output: Contribution to journalArticle

Tomasetti, C, Montemitro, C, Fiengo, ALC, Santone, C, Orsolini, L, Valchera, A, Carano, A, Pompili, M, Serafini, G, Perna, G, Vellante, F, Martinotti, G, Giannantonio, MD, Kim, YK, Nicola, MD, Bellomo, A, Ventriglio, A, Fornaro, M & Berardis, DD 2019, 'Novel pathways in the treatment of major depression: Focus on the glutamatergic system', Current Pharmaceutical Design, vol. 25, no. 4, pp. 381-387. https://doi.org/10.2174/1381612825666190312102444
Tomasetti C, Montemitro C, Fiengo ALC, Santone C, Orsolini L, Valchera A et al. Novel pathways in the treatment of major depression: Focus on the glutamatergic system. Current Pharmaceutical Design. 2019 Jan 1;25(4):381-387. https://doi.org/10.2174/1381612825666190312102444
Tomasetti, Carmine ; Montemitro, Chiara ; Fiengo, Annastasia L.C. ; Santone, Cristina ; Orsolini, Laura ; Valchera, Alessandro ; Carano, Alessandro ; Pompili, Maurizio ; Serafini, Gianluca ; Perna, Giampaolo ; Vellante, Federica ; Martinotti, Giovanni ; Giannantonio, Massimo D. ; Kim, Yong Ku ; Nicola, Marco D. ; Bellomo, Antonello ; Ventriglio, Antonio ; Fornaro, Michele ; Berardis, Domenico D. / Novel pathways in the treatment of major depression : Focus on the glutamatergic system. In: Current Pharmaceutical Design. 2019 ; Vol. 25, No. 4. pp. 381-387.
@article{518f0039b77d45abbec41ec95bc72303,
title = "Novel pathways in the treatment of major depression: Focus on the glutamatergic system",
abstract = "Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further “neurobiological targeted” approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.",
keywords = "Antidepressants, Antipsychotics, Depressive disorders, Glutamate, Ketamine, Mglur, Nmda, Postsynaptic density",
author = "Carmine Tomasetti and Chiara Montemitro and Fiengo, {Annastasia L.C.} and Cristina Santone and Laura Orsolini and Alessandro Valchera and Alessandro Carano and Maurizio Pompili and Gianluca Serafini and Giampaolo Perna and Federica Vellante and Giovanni Martinotti and Giannantonio, {Massimo D.} and Kim, {Yong Ku} and Nicola, {Marco D.} and Antonello Bellomo and Antonio Ventriglio and Michele Fornaro and Berardis, {Domenico D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1381612825666190312102444",
language = "English",
volume = "25",
pages = "381--387",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Novel pathways in the treatment of major depression

T2 - Focus on the glutamatergic system

AU - Tomasetti, Carmine

AU - Montemitro, Chiara

AU - Fiengo, Annastasia L.C.

AU - Santone, Cristina

AU - Orsolini, Laura

AU - Valchera, Alessandro

AU - Carano, Alessandro

AU - Pompili, Maurizio

AU - Serafini, Gianluca

AU - Perna, Giampaolo

AU - Vellante, Federica

AU - Martinotti, Giovanni

AU - Giannantonio, Massimo D.

AU - Kim, Yong Ku

AU - Nicola, Marco D.

AU - Bellomo, Antonello

AU - Ventriglio, Antonio

AU - Fornaro, Michele

AU - Berardis, Domenico D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further “neurobiological targeted” approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.

AB - Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further “neurobiological targeted” approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.

KW - Antidepressants

KW - Antipsychotics

KW - Depressive disorders

KW - Glutamate

KW - Ketamine

KW - Mglur

KW - Nmda

KW - Postsynaptic density

UR - http://www.scopus.com/inward/record.url?scp=85067597152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067597152&partnerID=8YFLogxK

U2 - 10.2174/1381612825666190312102444

DO - 10.2174/1381612825666190312102444

M3 - Article

VL - 25

SP - 381

EP - 387

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 4

ER -